Oxytocin antagonists with changes in the Asn5 position shed light on hormone-oxytocin receptor interactions.
Since oxytocin agonists and antagonists have different structure-activity relationships, we have investigated the stereostructural and stereoelectronic requirements of the Asn5 residue in oxytocin antagonists by the synthesis of four analogues of the potent, prolonged acting oxytocin antagonist [Pen1,D-Phe2,Thr4,Orn8]-oxytocin (I) in which Asn5 was replaced respectively with Thr (II), Leu5 (III), Asp5 (IV) and Tyr5 (V). These analogues had pA2 values in the antioxytocic in vitro rat uterine assay of 7.23 (I), 7.16 (II), 6.67 (III), 7.21 (IV), and 6.76 (IV), respectively. All were also found to be weakly potent in the in vivo anti-vasopressor assay in the rat. These studies demonstrate very different structural and stereoelectronic requirements for oxytocin agonists and antagonists when they interact with the oxytocin uterine receptor.
Hill
P S
PS
Department of Chemistry, University of Arizona, Tucson.
Chan
W Y
WY
Hruby
V J
VJ
D000595:Amino Acid Sequence; D000818:Animals; D001216:Asparagine / Q000737:chemistry*; D004338:Drug Combinations; D005260:Female; D005973:Glutamine; D008969:Molecular Sequence Data; D010121:Oxytocin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D011945:Receptors, Angiotensin / Q000378:metabolism; D018045:Receptors, Oxytocin; D012694:Serine; D013329:Structure-Activity Relationship; D014590:Uterine Contraction / Q000187:drug effects
D004338:Drug Combinations; D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; D005973:Glutamine; C071501:oxytocin, Pen(1)-Phe(2)-Thr(4)-Orn(8)-; D012694:Serine; D010121:Oxytocin; D001216:Asparagine